U.S. Markets closed

Dyadic International, Inc. (DYAI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.1200-0.0100 (-0.47%)
At close: 03:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.1300
Bid2.1200 x 800
Ask2.1400 x 800
Day's Range2.0900 - 2.1400
52 Week Range1.7400 - 6.8900
Avg. Volume63,454
Market Cap59.528M
Beta (5Y Monthly)0.24
PE Ratio (TTM)N/A
EPS (TTM)-0.3910
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.33
  • Zacks Small Cap Research

    DYAI: First Quarter 2022 Operational & Financial Results

    By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) released 2021 operational and financial results in a press release on May 12, 2022, subsequently filing its 10-Q with the SEC and hosting a conference call with investors. Highlights for the first quarter and to-date include: ➢ Exclusive animal health license agreement with Phibro -

  • GlobeNewswire

    Dyadic Reports First Quarter 2022 Financial Results and Highlights Recent Company Developments

    New research, license, and collaboration agreement with a Global Food Ingredients Company using Dyadic’s proprietary biotechnologiesLicense agreement with Phibro/Abic Animal Health to develop and commercialize animal vaccine(s)Advancing first-in-human clinical trial application (CTA) to South African Health Products Regulatory Authority (SAHPRA) to support clinical safety of C1 produced proteinsC1 produced COVID-19 monoclonal antibody (mAb) demonstrated broad neutralization and protection agains

  • GlobeNewswire

    Dyadic Announces Research, License and Collaboration for the Manufacture of Animal Free Ingredients

    JUPITER, Fla., May 11, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary protein production platform, today announced that it has entered into a Joint Development Agreement (“Agreement”) with a Global Food Ingredients Company to develop and manufacture a number of animal free ingredient products using the company’s biotechnologies.